Sign in
Active, not recruitingPhase 4

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

Key facts

Who runs it
BeiGene
Where
China6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
16 people enrolled
Started
17 Oct 2025
Expected to end
31 Oct 2028
Type of study
Interventional
Treatments tested
  • Zanubrutinib
Record updated
10 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Clinical and definitive histologic diagnosis of WM. Participant must be treatment-naive
  • Participant must meet at least 1 criterion for treatment according to consensus panel criteria from the Seventh International Workshop on Waldenström's macroglobulinemia (IWWM)
  • Participant must have measurable disease, as defined by serum immunoglobulin M (IgM) level > 0.5 g/dL
  • Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
  • Participants must have adequate organ function as indicated by the following laboratory values ≤ 7 days before the first dose of study treatment:; Participants must not have required blood transfusion or growth factor support ≤ 7 days before sample collection at screening for the following:; Absolute neutrophil count (ANC) ≥ 0.75 x 10\^9/L; Platelets ≥ 50 x 10\^9/L; Creatinine clearance of ≥ 30 ml/min as estimated by the Cockcroft-Gault formula; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN); Serum total bilirubin ≤ 2 x ULN (total bilirubin must be < 3 x ULN for participants with Gilbert syndrome)
  • Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for at least 1 month after the last dose of zanubrutinib. They must also have a negative urine or serum pregnancy test result ≤ 7 days before the first dose of study treatment

Who cannot take part

  • Central nervous system (CNS) involvement by WM. Patients with a history of CNS involvement must undergo magnetic resonance imaging (MRI) and cerebrospinal fluid cytology studies to document no evidence of CNS disease prior to study entry
  • Participants with any of the following cardiovascular risk factors:; Active cardiac ischemia (eg, cardiac chest pain) ≤ 28 days before first dose of study drug; Any history of acute myocardial infarction ≤ 6 months before the first dose of study drug; Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV (Appendix 7)≤ 6 months before the first dose of study drug; Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before the first dose of study drug; Active, clinically significant second-degree atrioventricular block Mobitz II, or third degree atrioventricular block; Any history of cerebrovascular accident ≤ 6 months before the first dose of study drug; Uncontrolled hypertension that cannot be managed by standard antihypertension medications ≤ 28 days before the first dose of study drug; Any episode of syncope or seizure ≤ 28 days before first dose of study drug
  • Participants requiring ongoing therapy with strong or moderate cytochrome CYP3A inducers
  • Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy, targeted therapy, or radiation therapy within 4 weeks, or antibody-based therapy within 4 weeks before the start of study drug
  • Major surgical procedure within 4 weeks before the start of study treatment (bone marrow aspirate and biopsy procedures are not considered major surgical procedures); Note: Other protocol defined criteria may apply
  • Evidence of disease transformation at the time of study entry
  • Evidence of disease transformation at the time of study entry
  • At the time of study entry, participants taking warfarin or other vitamin K antagonists

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.

The group in the trial

  • ZanubrutinibTreatment being tested

    Participants will receive 160 mg zanubrutinib orally twice a day until progressive disease, unacceptable toxicity or death, withdrawal of consent, loss to follow-up, or study termination by the sponsor for any reason.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 4, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Patients With Treatment-Naive Waldenström Macroglobulinemia
Record updated
10 August 2026